Wolverine (BPC-157 + TB-500)
Also known as Wolverine Blend
Studied for: combined repair blend
A combination of BPC-157 and TB-500 at 5mg each, pairing two of the most-studied repair-associated peptides. Research explores whether their distinct mechanisms are complementary.
Last reviewed September 26, 2026
How it is thought to work
The two compounds are studied for different steps in the repair sequence, BPC-157 for angiogenic and epithelial signaling, TB-500 for actin regulation and the migration of repair cells.
- Complementary MechanismsPairs a compound studied for vascular and epithelial signaling with one studied for cytoskeletal regulation and cell migration.
- Single ReconstitutionBoth compounds share a vial, so a protocol using each of them requires one preparation rather than two.
- Route studied
- Subcutaneous
- Research status
- Early clinical
The blend itself has not been studied as a combination, and published evidence for its components consists largely of BPC-157 reviews, mostly drawing on preclinical work, alongside a small human report on intra-articular BPC-157 for knee pain.
Research
What the research covers
What research examines
- Musculoskeletal soft tissue healing in BPC-157 research
- Wound healing in BPC-157 research
- BPC-157 in orthopaedic sports medicine literature
- Intra-articular BPC-157 in a small knee pain report
- Actin regulation and repair-cell migration associated with TB-500
- Possible complementarity of the two mechanisms
Reported effects in studies
- Human safety data are limited for both components
- The BPC-157 and TB-500 combination has not been evaluated as a blend in published studies
- Recent reviews have raised open questions about the risks as well as the reported benefits of BPC-157 for musculoskeletal use
- Adverse events are not systematically summarized in the available studies
Studied range
What research protocols have used
Research protocols have used 500–1,000 mcg per administration, once daily, with a loading phase before a lower-frequency maintenance phase, in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorRelated compounds
Researched alongside
- CJC-1295CJC-1295 without DAC, also called modified GRF 1-29, is a growth-hormone-releasing hormone analog with a short half-life, studied specifically for preserving the body's natural pulsatile release pattern.Read profile$119
- IpamorelinIpamorelin is a selective growth-hormone secretagogue. Research examines it specifically for its selectivity, releasing growth hormone with minimal effect on cortisol or prolactin.Read profile$79
- KPVKPV is the C-terminal tripeptide fragment of alpha-MSH. Research examines its anti-inflammatory profile, particularly within the gut, and its activity independent of pigmentation signaling.Read profile$69
- GHK-CuGHK-Cu is a copper-binding tripeptide studied for its role in skin, connective-tissue, and cellular renewal. Its recovery profile gives it a crossover into Foundation.Read profile$39
Studies
Cited research
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.
Cell and tissue research · 2019 · Review · PMID 30915550
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
Frontiers in pharmacology · 2021 · Review · PMID 34267654
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025 · Review · PMID 40756949
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
Alternative therapies in health and medicine · 2021 · PMID 34324435
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Current reviews in musculoskeletal medicine · 2025 · Review · PMID 40789979
FAQ
Questions about Wolverine (BPC-157 + TB-500)
Wolverine, also called the Wolverine Blend, is a combination of two repair-associated research peptides, BPC-157 and TB-500, supplied at 5 mg each in a single vial. The pairing brings together two of the most-studied peptides in repair research. Research interest centers on whether their distinct mechanisms are complementary, although the combination itself has not been evaluated as a blend in published studies. It is sold for laboratory research use only.
The two compounds are studied for different steps in the repair sequence. BPC-157 has been studied for angiogenic and epithelial signaling, meaning the formation of new blood vessels and the behavior of surface tissues. TB-500 has been studied for actin regulation and the migration of repair cells, involving the cytoskeleton. Because the mechanisms differ, researchers have explored whether combining them could cover more of the repair process than either compound alone.
Most published work concerns BPC-157. Reviews have examined its role in musculoskeletal soft tissue healing and wound healing, largely based on animal studies, and a systematic review has assessed its emerging use in orthopaedic sports medicine. A small human report described intra-articular BPC-157 for several types of knee pain. TB-500 has been studied for cell migration and actin regulation. No published studies evaluate the two compounds together as a blend.
Human safety data are limited for both components, and the combination has not been studied as a blend. Adverse events are not systematically summarized in the available studies. Recent narrative and safety-focused reviews of BPC-157 and other peptide therapies for musculoskeletal injuries have raised open questions about risk as well as benefit, reflecting the small amount of controlled human evidence. Findings from animal models may not translate to humans.
Research protocols have used 500 to 1,000 mcg per administration, once daily, by the subcutaneous route, with a loading phase before a lower-frequency maintenance phase. These protocols have run in 8-week blocks followed by 4 weeks off. Because both compounds share one vial, a protocol using both requires a single reconstitution rather than two. Each CoreX order ships with a protocol guide describing the research protocol in more detail.
Ask about Wolverine (BPC-157 + TB-500)
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.
Compare
Related comparisons
- Wolverine (BPC-157 + TB-500) vs Glow (BPC-157 + TB-500 + GHK-Cu)Wolverine (BPC-157 + TB-500) and Glow (BPC-157 + TB-500 + GHK-Cu) are research peptide blends built on the same two repair-associated peptides. Wolverine pairs BPC-157, studied for angiogenic and epithelial signaling, with TB-500, studied for actin regulation and repair-cell migration. Research has explored whether these mechanisms are complementary, and BPC-157 has been studied in soft tissue and wound healing. Glow adds GHK-Cu, the copper peptide most studied for copper-dependent collagen synthesis, skin remodeling, and gene expression. That added structural remodeling component is the main mechanistic difference. Neither blend has been evaluated as a combination in published studies. Human safety data are limited for both, and evidence for the components comes largely from preclinical work and reviews.